Cancer stem cells (CSCs) have been increasingly recognized as the key determinative
cells of malignancies. CD44 is a glycosylated cell surface receptor for hyaluronic acid
(HA) and many other extracellular matrix (ECM) components. It exists as a standard
isoform (CD44s) as well as a range of variants (CD44v) generated through alternative
splicing. Accumulating evidence suggests that CD44 is not only a CSC marker,
but also a critical regulator of CSC self-renewal, tumor initiation, metastasis,
and tumor chemo- and radioresistance properties.
|
 .jpg) 
|
|
_1.jpg)
|
|
.jpg)
|
|
![CD44 antibody [N1N2], N-term (GTX112893)](http://crm.itpison.com/Var/Elite/c2a6aa59-8bf2-427f-8dc3-577cbe86a674/EXTRA/images/CD44-antibody-%5bN1N2%5d-N-term-(GTX112893).jpg)
|
|
CD44 antibody
(GTX102111)  
|
|
CD44 antibody
(GTX102111)
|
|
CD44 antibody [N1N2],
N-term (GTX112893)
|
|
WB analysis to detect CD44 in wild-type (WT) or CD44 knockout (KO) HeLa cells.
|
|
WB analysis to detect CD44s (standard isoform) and CD44v (isoform variants) in several human cell extracts.
|
|
IHC-P analysis to detect CD44 in a human breast carcinoma tissue section.
|
|
|
|
|
![CD44 antibody [GT462] (GTX628895)](http://crm.itpison.com/Var/Elite/c2a6aa59-8bf2-427f-8dc3-577cbe86a674/EXTRA/images/CD44-antibody-%5bGT462%5d-(GTX628895).jpg)
|
|
![CD44 antibody [GT462] (GTX628895)](http://crm.itpison.com/Var/Elite/c2a6aa59-8bf2-427f-8dc3-577cbe86a674/EXTRA/images/CD44-antibody-%5bGT462%5d-(GTX628895)---.jpg)
|
|
![CD44 antibody [GT981] (GTX628472)](http://crm.itpison.com/Var/Elite/c2a6aa59-8bf2-427f-8dc3-577cbe86a674/EXTRA/images/CD44-antibody-%5bGT981%5d-(GTX628472)--.jpg)
|
|
CD44 antibody [GT462] (GTX628895)
|
|
CD44 antibody [GT462] (GTX628895)
|
|
CD44 antibody [GT981](GTX628472)
|
|
WB analysis to detect CD44 in extracts from MDA-MB-231 cells untreated (-) or treated (+) with Tunicamycin for 16 hours to inhibit N-glycosylation.
|
|
Flow cytometry analysis to detect CD44 in HL-60 cells.
|
|
ICC/IF analysis to detect CD44 on A431 cell membranes.
|
|
